Insulet Corporation $PODD Stock Holdings Increased by Eversept Partners LP

Eversept Partners LP raised its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 63.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,708 shares of the medical instruments supplier’s stock after acquiring an additional 29,104 shares during the period. Insulet makes up 1.1% of Eversept Partners LP’s holdings, making the stock its 22nd largest position. Eversept Partners LP owned approximately 0.11% of Insulet worth $21,235,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet during the 4th quarter valued at $26,000. Elyxium Wealth LLC bought a new stake in Insulet during the 4th quarter valued at $28,000. DV Equities LLC bought a new stake in Insulet during the 4th quarter valued at $28,000. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA raised its stake in Insulet by 68.8% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 55 shares in the last quarter.

Insider Activity

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.36% of the stock is owned by company insiders.

Insulet Stock Down 2.8%

PODD opened at $143.52 on Thursday. Insulet Corporation has a one year low of $140.63 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock’s fifty day moving average is $166.47 and its 200-day moving average is $228.11. The company has a market capitalization of $9.94 billion, a PE ratio of 33.38, a P/E/G ratio of 1.16 and a beta of 1.13.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts predict that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the topic of a number of research reports. Stifel Nicolaus dropped their price objective on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. JPMorgan Chase & Co. dropped their price objective on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Sanford C. Bernstein dropped their price objective on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Finally, William Blair initiated coverage on Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating on the stock. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $240.78.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.